Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
"what makes Eroxon unique is the way these ingredients are combined, using a proprietary technology"
Soup!
The ingredients in Eroxon® gel — ethanol, propylene glycol, glycerine (also known as glycerol), carbomer and potassium hydroxide - have a long history of pharmaceutical and cosmetic use and a strong safety profile.
However, what makes Eroxon unique is the way these ingredients are combined, using a proprietary technology.
I've read that ROC article, but I'm fairly certain they must be mistaken. I don't believe the FDA would class Eroxon as a medical device if it contained any drug or synthetic hormone. Or have I been reading too many of LiarBOoth's obnoxious posts?
If you goggle Eroxon a number of pharmaceutical websites( eg ROC Private) state that it contains Alprostadil,a synthetic version of a naturally occurring hormone that helps dilate blood vessels.Am I missing something?are there any scientists out there who can elucidate.
The Boots reviews are being trolled.
Look at the way the thumbs up, or down numbers go in approx the same pattern
It's the same person going through periodically and hitting the like or dislike button.
The reviews all have the same phrases and tone.
No real in depth feedback just the usual "waste of money"
Boots and Futura are aware of the " contrived reviews" it was mentioned in their presentation a couple.of weeks back at about the 9-10min mark if I remember rightly.
As was the patent protection process they are hoping to get for the gel formulation ratios.
Just looked at Amazon sales, 7,000 plus in last month! Am I wrong or did I see that it as about 2000 last month. If so that is a bit of an increase!
I agree. Furthermore, the results showed that Eroxon works in approx 60% of men so I think any advertising/packaging should mention this possibility otherwise there will be many more disgruntled customers posting negative reviews
Just had a look at the most recent reviews.They are all very negative.Two things stand out.Firstly the reviews are from verified purchases.Secondly the reviews seem to indicate that Eroxon has only been used once or twice before the conclusion is reached that it does not work.At the risk of repeating myself you clearly have to use the gel a number of times before it starts to work.It may well state this in the instructions.But who in reality studies the fine print of any medication leaflet? I think that this is a significant marketing problem.The negative reviews are drowning out any positive outcomes.This is surely something that needs addressing as a matter of urgency.
Regarding Patent! FUM’s Eroxon is based on patented Dermasys technology that is what causes the rapid cooling & heating sensation that gives an erection. IMO they can’t patent the heating & cooling effect as many products do this, but Dermasys somehow penetrates the skin, so guessing this process is what causes this cooling/heating, not a surface re-action much deeper and not easily replicated, so far easier to patent U would have thought.
Ref the patent. Success rate? Significant risk of not obtaining an extended patent?
This is my only fear and feel a large part of whats keeping this down.
Dano71, Fum sp is performing very well in comparison to most shares. The markets have been going down for over 2 years and since 2019 if include covid. Once sales figures are released (which could be anytime, it doesn’t have to quarterly update) which are expected to staggering from the comment of Fum marketing partner, then the sp will motor for sometime, imo.
IMO which comes from being involved in the scale out of a product like this before, its "In the Bag" for me the figures speak for themselves. The product is proven to work for 67% of people, not to mention the audience that will take for added boost. It advantages speak for themselves over their competitors. They don't get this far down the road without all key players ready to go! I don't believe any negotiations are taking place now in US, I think this would have been done a long time ago & they are just crossing T's & dotting I's ready to scale out. All parties knew the potential of this & I don't think there was any surprises with the scale out from boots. Once official revenue figures start coming in over all territories & new dist's come on board the SP should start to rise. I can't see any negatives here. People regardless of web reviews will always go "it might work for me" & try, so no issues there. I think what does need advertising is a clear instruction on reapplication for those that are not immediate responders. Clear instruction that gel may start to work with further applications (& provide the science behind that) or else it could be seen as a ploy to get non responders to buy more before they give up on it. I think for all us investors this will be somewhat of a slow burn for the next 6 mths until momentum build, but IMO will gain market share quite quickly once brand takes hold. Trust my patience is struggling but I think once sales starting happening all over, its going to be very exciting times ahead!
How do you get to know the sales of Eroxon that Boots have made - is there a link?
Fully Agree with Jet7 and martinelwick. FUM are showing lack of frontal lobe thinking.
FUM knowing the facts (that multiple usage bring on best results) should have designed a launch trial pack with free additional tubes. Positive results vs cost - Prudent marketing! Hopefully, this will be a learning curve for US launch.
Two articles published today (shares mag and hbw ) are very encouraging and should entice small PI,s.
IMO - Whilst US deals or sales figures are obviously key milestones, unless 3% plus investors show up the SP will fluctuate, aided and abetted by day traders. Unless people who are paid to research, analyse and invest show confidence and buy-in, the SP will continue to languish at these levels.
You’ve nailed it Martinelwick, we need patients, there will be many players looking to take this on in America. Negotiations are going to be hard, FUM will want the best deal, likewise partners are not going to jump in on a wing and a prayer. They will be looking very closely at the data from Europe.
Regarding Eroxon taking several attempts to work, FUM should have had this in mind from launch after feedback from the American trial, I have not as yet read through the leaflet accompanying the gels, but surely they have raised this point. Perhaps they have missed a trick in not offering a cheaper deal when buying multiple packs, just seems scandalous that they sell 3 x packs at £75 to me especially when they are trying to entice long term usage.
....Gets Off To Flying Start In The UK
https://hbw.pharmaintelligence.informa.com/RS153806/A-Phenomenon--Futuras-Eroxon-ED-Gel-Gets-Off-To-Flying-Start-In-The-UK
There is little point in referring back to the days when the share price was£1.There has been a massive increase in the number of shares since those days.
Referring back to an earlier post I remind you that in the investor presentation there was considerable confidence in securing the patent extension.
My take on the USA situation is that Walgreen(who own Boots) will wish to see the sales data in this country before committing themselves.
One thing that concerns me is that it emerged in said presentation that you may have to use Eroxon several times before it’s effective.At £25 a pop it’s easy to see why punters use the first pack with little positive results and post a negative review rather than fork out another £25 and try again.This will be in contrast to the trials where Eroxon was provided for no cost.
I don’t know how FUM convince people to give Eroxon another go.
My instinct is Eroxon is effective in about 40% of uses not the over 60% reported in the trials.This is still the basis for a profitable business model.Moreover although it cannot be articulated I am sure the recreational market is massive.
I've held these shares since before the deal agreed with SSL. I've seen the shares hit £1 and bounce around on potential good news . Now they have all the approvals and the SP should be moving it stalls .
I have a swimming pool to put in ffs and I want to be able to use the thing before I'm too old.
Sorry rant over .
Thanks the link works...imo..........lol hahaha
It does indeed .fair point.
Emphasizes also the pent up potential of this stock to become market leader. In a $3B market.
I'll take that.
Emphasises the potential importance of getting patent extension.
Https://www.sharesmagazine.co.uk/article/the-tiny-company-hoping-to-make-it-big-after-us-breakthrough see if this works
Hi Bazzamn
Link doesn't work for me, as says page not found. Are you able to copy and paste the article.
Https://www.sharesmagazine.co.uk/article/the-tiny-company-hoping-to-make-it-big-after-us-breakthrough.
Nice article today in Shares Mag.
GLA